AIM ImmunoTech

Founded in 1990, the bio-pharmaceutical cancer research company has 32 employees and was renamed from Hemispherx Biopharma to AIM Immunotech on September 3, 2019. It has two products, Alferon® and unapproved Ampligen/rintatolimod. In the late 1980s, AIM ImmunoTech partnered with Dupont to start clinical trials for Ampligen. After a couple years, Dupont severed its business relationship with AIM ImmunoTech. In 1998 and 2000, Hemispherx received notices of violation from the FDA for promoting rintatolimod as safe and effective before FDA approval, in violation of the Federal Food, Drug, and Cosmetic Act. An investor presentation from April 2020 admits AIM began testing Ampligen, still experimental, as a treatment for COVID-19 in January.